[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jinan Central Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":66},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100601905",false,"NCT07116577","Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC","A Single-Arm, Exploratory Study of Palliative Radiotherapy Combined With Iparomlimab and Tuvonralimab, Trifluridine\u002FTipiracil (TAS-102), and Bevacizumab in Later-Line Treatment of Advanced Colorectal Cancer","Inclusion Criteria:\n\n* Aged 18 to 75 years .\n* Histologically confirmed unresectable colorectal adenocarcinoma.\n* Patients must have received at least one prior line of oxaliplatin-, irinotecan-, or 5-FU-based therapy with documented progression or intolerance.\n* Documented KRAS and BRAF mutation status (mutant or wild-type) must be available.\n* Palliative radiotherapy targeting primary or metastatic lesions is planned.\n* At least one measurable lesion per RECIST v1.1 exists.\n* ECOG score of 0-1 and life expectancy ≥12 weeks.\n* Adequate bone marrow, hepatic, and renal function must be demonstrated.\n* Fertile patients commit to using effective contraception during and for 6 months post-treatment.\n\nExclusion Criteria:\n\n* History of Grade ≥3 immune-related adverse events (irAEs) from prior immunotherapy deemed contraindications for retreatment.\n* Radiation or systemic anticancer therapy within 14 days prior to first study treatment.\n* Active CNS metastases and\u002For leptomeningeal disease (LMD). Symptomatic interstitial lung disease (ILD), active pneumonitis, uncontrolled infections, or non-healing wounds\u002Ffistulae.\n* Intestinal perforation risks: active diverticulitis, intra-abdominal abscess, GI obstruction, or cancer-related peritoneal carcinomatosis.\n* Uncontrolled or symptomatic serous cavity effusions (pleural, ascites, pericardial).\n* Uncontrolled cardiovascular\u002Fcerebrovascular diseases.\n* Medical\u002Fsocial conditions that may compromise study results or lead to premature termination per investigator judgment.","ALL","18 Years","75 Years",{"count":19,"type":20},37,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This single-center, single-arm, prospective study plans to enroll patients with advanced colorectal cancer who have failed first-line or higher systemic therapies. Participants will receive a combination of iparomlimab and tuvonralimab (QL1706), trifluridine\u002Ftipiracil (TAS-102), bevacizumab, and palliative radiotherapy. The efficacy and safety of this combination therapy will be evaluated by assessing objective response rate (ORR), progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety profile.",[26],"mCRC","NOT_YET_RECRUITING","2025-08-06",{"date":30,"type":31},"2025-08-11","ACTUAL",{"date":33,"type":20},"2025-08-31",{"date":35,"type":20},"2028-12-31",{"name":37,"class":38},"Jinan Central Hospital","OTHER",1,{"id":41,"slug":4,"hasResults":10,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":45,"targetDuration":47,"studyType":48,"phases":4,"briefSummary":49,"conditions":50,"keywords":53,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":39},"100558219","NCT06548269","Multimodal Prognostic Assessment of Acute Ischemic Stroke Patients With Atrial Fibrillation: a Prospective, Multicenter, Observational Study (IAT-CLOSURE)","Inclusion Criteria:\n\n1. Age \\> 18 years old；\n2. Acute ischemic stroke with onset ≤ 14 days；\n3. Previously or during this hospitalization diagnosed with non-valvular atrial fibrillation;\n4. Informed consent obtained from the patient or his\u002Fher legal representative；\n\nExclusion Criteria:\n\n1. Pacemaker, implantable cardioverter defibrillator or implantable cardiac monitor;\n2. Left atrial appendage has been removed or post occlusion device implantation;\n3. Transient AF secondary to other reversible disorders；\n4. Life expectancy less than 1 year;\n5. Patients that cannot complete subsequent follow-up (e.g. no fixed residence, overseas patients, etc.);\n6. Females who are pregnant or in lactation;\n7. Participating in other clinical trials that could confound the evaluation of the study;\n8. Other circumstances that the investigator considers inappropriate for participation or may pose a significant risk to patients.",{"count":46,"type":20},1000,"3 Years","OBSERVATIONAL","The main purpose of this study is to investigate the safety and outcomes of different treatment strategies, including best medical therapy (OAC \\[oral anticoagulation\\], antiplatelet \\[APT\\]) and left atrial appendage closure \\[LAAC\\] in acute ischemic stroke (AIS) patients with atrial fibrillation (AF) based on multimodal assessment from combined brain and cardiologic work-up, and to optimize secondary prevention.",[51,52],"Acute Ischemic Stroke","Atrial Fibrillation",[51,54,55,56],"Atrial fibrillation","AF burden","Left atrial appendage closure","RECRUITING","2025-05-19",{"date":60,"type":31},"2025-05-22",{"date":62,"type":31},"2024-11-15",{"date":64,"type":20},"2029-05-31",{"name":37,"class":38},""]